<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04312698</url>
  </required_header>
  <id_info>
    <org_study_id>A83_03DL/HT1903</org_study_id>
    <nct_id>NCT04312698</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Efficacy and Safety of CKD-386</brief_title>
  <official_title>A Randomized, Double-blind, Multi-center, Therapeutic Confirmatory, Phase III Trial to Evaluate the Efficacy and Safety of D013, D326 and D337 Combination Therapy in Dyslipidemia Patients With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical Trial to Evaluate the Efficacy and Safety of CKD-386&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 29, 2019</start_date>
  <completion_date type="Actual">June 18, 2021</completion_date>
  <primary_completion_date type="Actual">June 18, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change rate from baseline in LDL-C</measure>
    <time_frame>8 weeks after drug administrations</time_frame>
    <description>Compare experimental group 1 with comparator group 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in MSSBP</measure>
    <time_frame>8 weeks after drug administrations</time_frame>
    <description>Compare experimental group 1 with comparator group 2</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Dyslipidemia Patients With Hypertension</condition>
  <arm_group>
    <arm_group_label>Experimental Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator Group 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D013, D326, D337</intervention_name>
    <description>Experimental: Group 1 Patients assigned to this group are treated with D013, D326, D337</description>
    <arm_group_label>Experimental Group 1</arm_group_label>
    <other_name>Drugs are consist of antihypertensive agent and antihyperlipidemic agent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo of D013, D326, D337</intervention_name>
    <description>Placebo Comparator: Group 1 Patients assigned to this group are treated with D326, D337, placebo of D013</description>
    <arm_group_label>Comparator Group 1</arm_group_label>
    <other_name>Drugs are consist of antihypertensive agent and antihyperlipidemic agent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D013, placebo of D326, placebo of D337</intervention_name>
    <description>Placebo Comparator: Group 2 Patients assigned to this group are treated with D013, placebo of D326, placebo of D337</description>
    <arm_group_label>Comparator Group 2</arm_group_label>
    <other_name>Drugs are consist of antihypertensive agent and antihyperlipidemic agent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects are diagnosed with Dyslipidemia Patients with Hypertension or are being&#xD;
             administered anti-hypertension and anti-hypertension drugs after diagnosis.&#xD;
&#xD;
          2. Subjects who agreed to participate in this clinical trial voluntarily.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who were satisfied specific blood pressure levels that measured at screening&#xD;
             period.&#xD;
&#xD;
          2. Subjects who were satisfied specific lipid levels that measured at screening period.&#xD;
&#xD;
          3. Subjects who cannot participate in a clinical trial based on the PI's judgment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Yonsei University Medical Center Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 12, 2020</study_first_submitted>
  <study_first_submitted_qc>March 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2020</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antihypertensive Agents</mesh_term>
    <mesh_term>Hypolipidemic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

